The efficacy of a single chain recombinant equine luteinizing hormone (reLH) in mares: Induction of ovulation, hormone profiles, and inter-ovulatory intervals

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorYoon, M. J.
dc.creatorBolme, I.
dc.creatorColgin, M.
dc.creatorNiswender, K. D.
dc.creatorKing, S. S.
dc.creatorAlvarenga, M.
dc.creatorJablonka-Shariff, A.
dc.creatorPearl, C. A.
dc.creatorRoser, J. F.
dc.date2014-02-26T17:01:00Z
dc.date2014-05-20T13:41:44Z
dc.date2016-10-25T16:56:43Z
dc.date2014-02-26T17:01:00Z
dc.date2014-05-20T13:41:44Z
dc.date2016-10-25T16:56:43Z
dc.date2007-11-01
dc.date.accessioned2017-04-05T20:42:25Z
dc.date.available2017-04-05T20:42:25Z
dc.identifierDomestic Animal Endocrinology. New York: Elsevier B.V., v. 33, n. 4, p. 470-479, 2007.
dc.identifier0739-7240
dc.identifierhttp://hdl.handle.net/11449/14483
dc.identifierhttp://acervodigital.unesp.br/handle/11449/14483
dc.identifier10.1016/j.domaniend.2007.06.001
dc.identifierWOS:000250527800012
dc.identifierhttp://dx.doi.org/10.1016/j.domaniend.2007.06.001
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/861605
dc.descriptionThe objectives of this study were to determine the efficacy of recombinant equine luteinizing hormone (reLH) in shortening the time to ovulation in cycling mares and to determine the effects of treatment on endogenous hormones and inter-ovulatory intervals. In study 1, mares of light horse breeds (3-20 years) were treated with either a vehicle, various doses of reLH, or human chorionic gonadotropin (hCG). Cycling mares were examined by palpation and ultrasound per rectum daily or every 12 h from the time of treatment to ovulation. In studies 2 and 3, jugular blood samples were collected daily or every 12 h from the time of treatment to ovulation for analysis of LH, follicle stimulating hormone (FSH), estradiol-17 beta (E-2), and progesterone (P-4) by radioimmunoassays (RIA). Increasing doses of reLH (0.3, 0.6, 0.75, and 0.9 mg) showed increasing effectiveness at inducing ovulation within 48 h of treatment. Treatments with the 0.75 and 0.9 mg doses of reLH resulted in 90% and 80% ovulation rates, which were similar to hCG treatment (85.7%). Except for the early rise in LH after treatment with 0.5, 0.65, and 1.0 mg of reLH, hormone profiles appeared to be similar between control and treated cycles. Inter-ovulatory intervals were similar between control and treatment cycles. In conclusion, reLH is a reliable and effective ovulatory agent that does not significantly alter endogenous hormone profiles or affect inter-ovulatory intervals.(c) 2007 Elsevier B.V. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationDomestic Animal Endocrinology
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectrecombinant single chain
dc.subjectequine
dc.subjectLH
dc.subjectin vivo
dc.subjectmare
dc.titleThe efficacy of a single chain recombinant equine luteinizing hormone (reLH) in mares: Induction of ovulation, hormone profiles, and inter-ovulatory intervals
dc.typeOtro


Este ítem pertenece a la siguiente institución